Segment Information

3 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

Segment Information

Segment InformationWe operate as one operating segment with a focus on the development and commercialization of products to address the unmet needs of patients with chronic and life-threatening conditions. Our Chief Executive Officer, as our chief operating decision maker, manages and allocates resources to the operations of our company on a consolidated basis. This enables our Chief Executive Officer to assess our overall level of available resources and determine how best to deploy these resources across functions, therapeutic areas, and research and development projects in line with our long-term company-wide strategic goals.

Total revenues, cost of sales, and gross profit (loss) for each of our commercial products and other were as follows (in millions):

	Three Months Ended March 31,
2023		Tyvaso(1)		Remodulin(2)		Orenitram		Unituxin		Adcirca		Other		Total
Total revenues		$	238.4	$	121.4	$	88.2	$	49.1	$	7.3	$	2.5	$	506.9
Cost of sales		26.9		6.9		7.6		4.7		3.1		3.1		52.3
Gross profit (loss)		$	211.5	$	114.5	$	80.6	$	44.4	$	4.2	$	(0.6)	$	454.6
2022
Total revenues		$	172.0	$	131.7	$	82.8	$	55.6	$	9.8	$	10.0	$	461.9
Cost of sales		6.2		7.2		5.2		3.3		4.0		—		25.9
Gross profit		$	165.8	$	124.5	$	77.6	$	52.3	$	5.8	$	10.0	$	436.0

(1) Total revenues and cost of sales include both the drug product and the respective inhalation devices for both Tyvaso and Tyvaso DPI.

(2) Total revenues and cost of sales include sales of infusion devices, such as the Remunity Pump.

Geographic revenues are determined based on the country in which our customers (distributors) are located. Total revenues from external customers by geographic area are as follows (in millions):

	Three Months Ended March 31,
	2023		2022
United States	$	469.7	$	409.8
Rest of World	37.2		52.1
Total	$	506.9	$	461.9

We recorded revenue from three distributors in the United States that exceeded ten percent of total revenues. Revenue from these three distributors as a percentage of total revenues is as follows:

	Three Months Ended March 31,
	2023		2022
Distributor 1	50	%	47	%
Distributor 2	33	%	29	%
Distributor 3	9	%	10	%